Study Provides Support for TKI Discontinuation in Some Patients With CML
This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.
Diagnosis & Disease Information
Chemotherapy-Free Regimen Consisting of 3 Novel Agents for Previously Untreated, Poor Prognosis CLL
In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.
Addition of Venetoclax to Azacitidine Associated With Clinically Significant OS Benefit in AML
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
Increasing Factor IX Levels May Be Independent of Puberty in Children With Hemophilia B Leyden
Genetic mutations associated with the heterogeneity of hemophilia B Leyden may also be linked to mechanisms that increase factor IX levels with age.
Underlying Primary Immunodeficiency May Contribute to Pediatric Bone Marrow Failure
Due to phenotypic overlap between bone marrow failure and primary immunodeficiency, researchers recommend accurate immunologic work-up.
Treatment Modifications Common Among Older Patients With cHL
Modifications of ABVD or CHOP were common among elderly patients with cHL and may contribute to their disproportionate excess mortality, signaling a need for less toxic regimens.
Identifying Optimal Immunochemotherapy for Patients With Mantle Cell Lymphoma
Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
Ixazomib Found Effective as a Maintenance Therapy in Patients With Newly Diagnosed MM Who Are Ineligible for Transplant
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
All Oral Proteasome Inhibitor-Containing Regimen in Transplant-Ineligible Multiple Myeloma
Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.
VTE-BLEED Score May Not Accurately Differentiate Patients With VTE for Bleeding Risk
VTE-BLEED prognostic scores did not accurately identify patients with VTE who were at high risk of bleeding events.
- Loading...
Loading...
Next post in EHA25 Virtual Congress
Loading... 
Loading...